- Home
- HUMAW
HUMAW
Humacyte Inc. Warrant
as 12-18-2024 12:37pm EST
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.
| Founded: | N/A | Country: | United States |
| Employees: | 185 | City: | DURHAM |
| Market Cap: | N/A | IPO Year: | 2020 |
| Target Price: | N/A | AVG Volume (30 days): | N/A |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | N/A | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Humacyte Inc. Warrant News
HUMAW Breaking Stock News: Dive into HUMAW Ticker-Specific Updates for Smart Investing
GlobeNewswire
16 days ago
Humacyte to Present at the Piper Sandler 36th Annual Healthcare Conference
GlobeNewswire
a month ago
Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH)
Simply Wall St.
a month ago
Insider Buyers At Humacyte Likely Disappointed With 17% Slide
GlobeNewswire
a month ago
Humacyte Clinical Results Highlighting Benefit of the ATEV™ in the Repair of Civilian and Military Arterial Injuries Published in JAMA Surgery
GlobeNewswire
a month ago
Humacyte Presents Preclinical Results of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting at American Heart Association’s Scientific Sessions 2024
GlobeNewswire
a month ago
Humacyte Announces Pricing of $15.0 Million Registered Direct Offering
GlobeNewswire
a month ago
Humacyte Third Quarter 2024 Financial Results and Business Update
GlobeNewswire
a month ago
Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 8, 2024
Compare HUMAW vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HUMAW Humacyte Inc. Warrant - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.